YD Bio Ltd (YDES) shareholders
Close on Nov 17, 2026Market cap $334.83MP/E –Yield –
Ownership
Who owns YD Bio's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Ethan Shen Joint filing with YD Biopharma Holding Limited (61.15%) | 54,345,011 | 77.06% | 13G (passive) amendment | Feb 17, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Ethan Shen PhD | CEO, Director | 54,379,189 | Sep 16, 2026 |
| Bo-Xiang Zhang | Chief Medical Officer, Director | 31,141 | Mar 27, 2026 |
| Man Edmund Hen | Chief Financial Officer | – | Mar 26, 2026 |
| Kochi Chang | Director | 10,965 | Oct 6, 2026 |
| Shao-Ta Lu | Director | 62,116 | Oct 6, 2026 |
| Jerry Yin-Chia Lee | Director | – | Mar 30, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Shao-Ta Lu Director | Sep 30, 2026 | Option exercise | +3,135 | – | – | 10,965 |
| Kochi Chang Director | Sep 30, 2026 | Option exercise | +3,135 | – | – | 10,965 |
| Ethan Shen PhD CEO, Director | Sep 14, 2026 | Buy | +12,700 | $3.85 | $48.90K | 11,258,331 |
| Ethan Shen PhD CEO, Director | Sep 9, 2026 | Buy | +3,100 | $3.93 | $12.18K | 11,245,631 |
| Ethan Shen PhD CEO, Director | Sep 4, 2026 | Buy | +18,378 | $3.67 | $67.45K | 11,242,531 |
| Shao-Ta Lu Director | Jun 30, 2026 | Option exercise | +5,749 | – | – | 7,830 |
| Kochi Chang Director | Jun 30, 2026 | Option exercise | +5,749 | – | – | 7,830 |
| Shao-Ta Lu Director | Mar 31, 2026 | Option exercise | +2,081 | – | – | 2,081 |
| Kochi Chang Director | Mar 31, 2026 | Option exercise | +2,081 | – | – | 2,081 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of YD Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 122,170 shares on Sep 28, 2026 over the last 90 days.
See a number that looks wrong?